Organization
Ohio State University Comprehensive Cancer Center
38 clinical trials
22 abstracts
Abstract
Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.Org: Weill Cornell Medicine, Mount Sinai Hospital-Breast Medical Oncology, Massachusetts General Hospital, UM/Sylvester Comprehensive Cancer Center, UNC Patient Advocates for Research Council,
Abstract
BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab.Org: ECOG-ACRIN Biostatistics Center, University Hospitals Seidman Cancer Center, University of Miami Sylvester Cancer Center, Ohio State University Comprehensive Cancer Center, Temple University Health System,
Abstract
Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance).Org: Columbus, OH, GZA-ZNA Hospitals, Joan and Sanford I Weill Medical College of Cornell University, Weill Cornell Medicine, New York, NY,
Clinical trial
A Pilot Study of Adaptive De-Intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal CancerStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
HNSALV Trial: Combining Immunotherapy With Salvage Surgery and IORT for Treatment of Persistent/Recurrent Head and Neck CancersStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL), Including Those Who Have Relapsed on Ibrutinib, or Patients With Untreated CLL/SLL/PLL and an Open Pilot Study for Patients With Richters Transformation (RT)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
The Effects of a Standardized Research E-Cigarette on the Human Lung: A Clinical Trial With Bronchoscopic BiomarkersStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase Ib Study of AZD9291 (Osimertinib) and BC2059 (Tegavivint) as First-Line Therapy in Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase II Trial Combining Hypofractionated Radiation Boost With Conventionally-Fractionated Chemoradiation in Locally Advanced Non-small Cell Lung Cancer Not Suitable for SurgeryStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
Low Anterior Resection Syndrome: Retrograde Enema Program vs Medical ManagementStatus: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase I Trial Targeting Mitochondrial Metabolism With Papaverine in Combination With Chemoradiation for Stage II-III Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Prospective Randomized Phase II Study of Acalabrutinib + Obinutuzumab or Venetoclax in Previously Untreated CLLStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Safely Stopping Pre-Medications in Patients Receiving Paclitaxel: A Randomized TrialStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin's LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase I Trial of MEK Inhibitor Trametinib in Combination With Neoadjuvant 5-Fluorouracil Chemoradiation in the Treatment of KRAS, BRAF, and NRAS-MUTANT Rectal CancersStatus: Completed, Estimated PCD: 2021-09-29
Clinical trial
Informing Oral Nicotine Pouch Regulations to Promote Public HealthStatus: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
The BE WELL Study: Black Raspberry Beverage Working to Prevent Lung CancerStatus: Completed, Estimated PCD: 2021-05-13
Clinical trial
A Phase 2 Study Using Stereotactic Ablative Radiation Therapy and Ipilimumab in Patients With Oligometastatic MelanomaStatus: Completed, Estimated PCD: 2020-08-03
Clinical trial
The Effect of a Soy Bread Diet Intervention on Immune Function in Men With Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2022-03-09
Clinical trial
A Phase I Trial Combining Papaverine and Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer or Lung MetastasesStatus: , Estimated PCD: 2024-12-31
Clinical trial
Phase 2 Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLLStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Pilot Study Testing the Effects of BTK Inhibitor Ibrutinib on Levels and Function of Myeloid Derived Suppressor Cells and Other Immune Subsets in Patients With Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2020-02-20
Clinical trial
A Tai Chi Intervention to Promote Smoking Cessation Among Cancer SurvivorsStatus: Not yet recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Pilot Trial of Topical vs Oral Minoxidil for Treatment of Endocrine Therapy-Induced Alopecia in Breast Cancer PatientsStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Dietary Fruit Bioactives and Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2013-08-01
Clinical trial
Letermovir for Cytomegalovirus Prophylaxis in Patients With Hematological Malignancies Treated With AlemtuzumabStatus: Active (not recruiting), Estimated PCD: 2024-04-09
Clinical trial
The Impact of Total Intravenous Anesthesia Following Cancer Surgery (TIVACS) StudyStatus: Completed, Estimated PCD: 2024-01-26
Clinical trial
An Investigator-Sponsored Phase 2 Single Arm Trial of Ramucirumab and Pembrolizumab in Patients With EGFR Mutant Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2023-08-19
Clinical trial
A Pilot Trial of Electronic Cigarettes in Patients Diagnosed With Cancers of the Head, Neck, and LungStatus: Withdrawn, Estimated PCD: 2024-01-31
Clinical trial
Investigating the Use of EMLA Topical Cream for Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Cutaneous CancersStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Open-Label Phase 2 Trial of Vyxeos in Patients With Intermediate and High-Risk Acute Myeloid Leukemia Who Have Failed an Initial Cycle of Standard Cytarabine and Daunorubicin ChemotherapyStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Randomized Phase I Study Assessing the Safety and Tolerability Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at Completion of Interval Cytoreductive Surgery Compared to Surgery and Chemotherapy Prior to Surgery for Patients With Stage III/IV Ovarian Cancer Undergoing Neoadjuvant Chemotherapy.Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Examining the Impact of Nicotine Pouches in Rural Ohio and Ohio AppalachiaStatus: Recruiting, Estimated PCD: 2024-03-31
Clinical trial
A Phase I/II, Open-Label, Multi-Center Study Evaluating the Safety and Efficacy of Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative NeoplasmsStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Comprehensive Evaluation of Tobacco-Flavored vs. Non-Tobacco Flavored E-Cigarettes on Smoking BehaviorStatus: Not yet recruiting, Estimated PCD: 2027-04-29
Clinical trial
Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2022-06-24
Clinical trial
Examining the Appeal of Nicotine Pouches in Ohio AppalachiaStatus: Completed, Estimated PCD: 2023-04-18
Clinical trial
A Phase Ib/II Study of the Safety and Pharmacology of Nilotinib to Prevent Paclitaxel-Induced Peripheral Neuropathy in Patients With Breast CancerStatus: Recruiting, Estimated PCD: 2024-01-02
Clinical trial
Detection of Sentinel Lymph Nodes in Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging: Comparison of Isosulfan Blue and Indocyanine Green Dyes With Fluorescence ImagingStatus: Completed, Estimated PCD: 2016-11-16
Clinical trial
Phase II Trial of Primary Endocrine Therapy With Combination of Fulvestrant or an Aromatase Inhibitor and Palbociclib in Elderly Patients With Hormone Responsive Breast Cancer Who Have Inoperable Tumor Or Operable Tumor But Cannot Undergo Surgery Due to Frailty Or Who Refuse SurgeryStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Comparison of Orgovyx (Relugolix) vs Eligard (Leuprolide) on Cardiovascular Function and Biomarkers During Standard of Care Combined ADT (Androgen Deprivation Therapy)-Radiation for Prostate CancerStatus: Not yet recruiting, Estimated PCD: 2027-12-31
Abstract
Novel STK11 differentiation phenotype classifier STK11-DPC: Immunosuppressive tumor microenvironment (TME) and response to immune checkpoint blockade (ICB) in STK11-deficient NSCLC.Org: The James Cancer Hospital and Solove Research Institute, Ohio State University Comprehensive Cancer Center, Ohio State University Comprehensive Canvcer Hospital, The Ohio State University - James Cancer Hospital, The Ohio State University Wexner Medical Center,
Abstract
Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study.Org: Lifespan Health System, Providence, RI, Ohio State University Comprehensive Cancer Center, Columbus, OH, Yale Cancer Center, Yale School of Medicine, New Haven, CT,
Abstract
Incorporating long non-coding RNA (lncRNA) into genome-wide biomarker screening for prognostic gene signatures of immunotherapy outcomes.Org: H. Lee Moffitt Cancer Center and Research Institute, Ohio State University Comprehensive Cancer Center, University of Virginia, Charlottesville, VA, USA, University of Colorado Denver Anschutz Medical Center, University of Southern California - Health Sciences Campus,
Abstract
A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer.Org: University of Texas Southwestern Medical Center, Memorial Sloan Kettering Cancer Center, CLION-CAM Group, Cedars-Sinai Medical Center, Cedars-Sinai Cancer,
Abstract
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.Org: SOLTI Cancer Research Group, Ohio State University Comprehensive Cancer Center, Novartis Pharmaceuticals, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, University of North Carolina School of Medicine,
Abstract
The Ohio State University Guardant Shield Colorectal Cancer Screening Project.Org: The Ohio State University Wexner Medical Center, Ohio State University Comprehensive Cancer Center, Ohio State University James Cancer Hospital and Solove Research Institute,
Abstract
Impact of obesity on the risk of immune-related adverse events (irAEs) among patients receiving immune-checkpoint inhibitors (ICI) treatment: A retrospective cohort study.Org: The Ohio State University College of Medicine, Ohio State University Comprehensive Cancer Center, Department of Biomedical Informatics, The Ohio State University, The Ohio State University - James Cancer Hospital,
Abstract
NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer.Org: University of Kansas Medical Center Comprehensive Cancer Center (KUMC CCC), NRG Oncology SDMC, The University of Pittsburgh, St. Luke’s University Health Network Cancer Center, Orlando Health Cancer Institute,
Abstract
BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.Org: Ohio State University Comprehensive Cancer Center, University of California, Irvine, Irvine, CA, Sir Charles Gairdner Hospital, Loxo Oncology at Lilly, Eli Lilly and Company,
Abstract
Retrospective analysis of the relationship between time to anti-resorptive therapy and incidence of skeletal related events in patients with multiple myeloma.Org: Sidney Kimmel Cancer Center at Thomas Jefferson University, Thomas Jefferson University Hospital, Sidney Kimmel Medical College of Thomas Jefferson University, Department of Pharmacology, Physiology, & Cell Biology at Thomas Jefferson University, Ohio State University Comprehensive Canvcer Hospital,
Abstract
Expression profiles of MUC5AC glycoforms in neoplastic and non-neoplastic pancreatic tissue.Org: Ohio State University Comprehensive Cancer Center, The Ohio State University - James Cancer Hospital, University of Virginia School of Medicine, Charlottesville, VA,
Abstract
The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing.Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Tempus Labs, Inc., David Geffen School of Medicine UCLA, Ohio State University Comprehensive Cancer Center,
Abstract
Sex differences in prognostic utility of peripheral eosinophil count in first-line immune checkpoint therapy against metastatic NSCLC.Org: Ohio State University Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The Ohio State University College of Medicine, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center, The Ohio State University Wexner Medical Center,
Abstract
BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.Org: Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, Faculty Hospital Hradec Kralove,
Abstract
Evaluating depth of disparities in relation to relative survival rates: Analysis of SEER data.Org: Ohio State University Wexner Medical Center, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Ohio State University Comprehensive Cancer Center, The Ohio State University - James Cancer Hospital,
Abstract
Predictors of response in advanced colorectal cancer (CRC) patients treated with immune-checkpoint inhibitors (ICI).Org: The Ohio State University College of Medicine, Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center, Wexner Medical Center and The James Cancer Hospital, Ohio State University,
Abstract
Clinicopathologic features and outcomes associated with induction regimen intensity among older veterans with myeloma.Org: University of New Mexico Health Sciences Center, Raymond G. Murphy New Mexico Veterans Affairs Medical Center, Ohio State University Comprehensive Cancer Center, Duke University and Durham VA Medical Centers, Michael E DeBakey VA Medical Center,
Abstract
Risk factors (RF) for poor outcomes in esophageal (EC) and gastric (GC) adenocarcinomas treated with immune-checkpoint inhibitors (ICI).Org: The Ohio State University College of Medicine, Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center, Wexner Medical Center and The James Cancer Hospital, Ohio State University,
Abstract
Real-world experience and outcomes of immune-checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC).Org: Ohio State University Comprehensive Canvcer Hospital, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, The Ohio State University Wexner Medical Center, Ohio State University Wexner Medical Center,